Since the neurodevelopmental outcomes in preterm infants after intravitreal injection of anti-VEGF agents remains unclear [19,20,21,22], the optimal dose of intravitreal anti-VEGF agent for A-ROP infants still needs to be investigated in future studies. Here, VEGFA is linked to retinopathy of prematurity.